Abstract
ABSTRACT The occurrence of PC considerably worsens the prognosis of cancers. The classic treatment yields an overall survival of below 5% at 5years. However, in 20% of the cases, the disease is exclusively peritoneal, and a treatment combining complete cytoreductive surgery (CCRS) plus hyperthermic intraperitoneal chemotherapy (HIPEC) has made it possible to achieve a major increase in 5-year overall survival. HIPEC is only proposed for treating residual infra-millimetric,PC and therefore, is logical and useful exclusively after CCRS. The current appropriate indications are as follows: For peritoneal pseudomyxomas (5-year OSR is above 80%). For colorectal PC (5-year OSR exceed 40%, with 18% of patients definitively cured). For mesotheliomas (the 5-year OSR is close to 58%) Current doubtful indications are as follows: For gastric tumours (the 5-year OSR is close to 15%). For ovarian cancers (OSR are very low when CCRS + HIPEC is used as a salvage treatment). For few rare PC (not detailed). Conclusion CCRS + HIPEC are the current gold standard therapy for peritoneal extension of pseudomyxoma, mesotheliomas and colorectal PC, for selected patients. Disclosure The author has declared no conflicts of interest.
Talk to us
Join us for a 30 min session where you can share your feedback and ask us any queries you have
Disclaimer: All third-party content on this website/platform is and will remain the property of their respective owners and is provided on "as is" basis without any warranties, express or implied. Use of third-party content does not indicate any affiliation, sponsorship with or endorsement by them. Any references to third-party content is to identify the corresponding services and shall be considered fair use under The CopyrightLaw.